MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Inicio・Lista de Acciones・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Cerrado

SectorSalud

14.21 3.35

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

13.81

Máximo

14.49

Métricas clave
By Trading Economics
Ingresos	-14M -25M
Ventas	-5.5M 66M
Margen de beneficio	-38.059
Empleados	342
EBITDA	-14M -19M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+59% upside

Dividendos
By Dow Jones
Próximas Ganancias	13 ago 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-169M 1.6B
Apertura anterior	10.86
Cierre anterior	14.21

Noticias sobre sentimiento de mercado

By Acuity

50%

157 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

12.42 / 14.93 Soporte y Resistencia

Arcutis Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 jul 2025, 15:46 UTC

Principales Movimientos del Mercado

BitMine Shares Fall After Closing of $250 Million Private Placement

9 jul 2025, 23:44 UTC

Charlas de Mercado

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 jul 2025, 23:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 jul 2025, 22:59 UTC

Charlas de Mercado

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 jul 2025, 22:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

9 jul 2025, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jul 2025, 20:26 UTC

Ganancias

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 jul 2025, 19:18 UTC

Charlas de Mercado

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 jul 2025, 19:03 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 jul 2025, 18:31 UTC

Charlas de Mercado

Some Fed Officials Supported Considering July Cut -- Market Talk

9 jul 2025, 17:07 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk -2-

9 jul 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 jul 2025, 16:14 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 16:14 UTC

Charlas de Mercado

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 jul 2025, 16:14 UTC

Adquisiciones, fusiones, absorciones

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 jul 2025, 16:12 UTC

Charlas de Mercado

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 jul 2025, 16:08 UTC

Charlas de Mercado

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 jul 2025, 15:31 UTC

Principales Movimientos del Mercado

BitMine Shares Fall After Closing of $250M Private Placement

9 jul 2025, 15:31 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 jul 2025, 15:27 UTC

Charlas de Mercado

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 jul 2025, 14:36 UTC

Adquisiciones, fusiones, absorciones

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 jul 2025, 14:31 UTC

Adquisiciones, fusiones, absorciones

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 jul 2025, 14:26 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

9 jul 2025, 14:26 UTC

Charlas de Mercado

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparación entre iguales

Cambio de precio

Arcutis Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

59% repunte

Estimación a 12 meses

Media 21.29 USD 59%

Máximo 29 USD

Mínimo 19 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

12.42 / 14.93Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentimiento

By Acuity

157 / 376 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.